−1.446EUR
−244.54 MEUR
66.21 MEUR
91.60 M
About CUREVAC NV
Sector
CEO
Alexander Zehnder
Headquarters
Tübingen
Website
Employees (FY)
1.05 K
Founded
2020
ISIN
NL0015436031
FIGI
BBG00WMMD779
CureVac BV is a clinical-stage biopharmaceutical company, which engages in developing transformative medicines based on messenger ribonucleic acid (mRNA). Its product portfolio includes clinical and preclinical candidates across multiple disease indications in prophylactic vaccines, oncology, and protein therapy. The company was founded by Ingmar Hoerr and Florian von der Mülbe in 2000 and is headquartered in Tübingen, Germany.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of 5CV is 2.58 EUR — it has increased by 2.96% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on FWB exchange CUREVAC NV stocks are traded under the ticker 5CV.
CUREVAC NV is going to release the next earnings report on Apr 24, 2024. Keep track of upcoming events with our Earnings Calendar.
One year price forecast for CUREVAC NV has a max estimate of 19.16 EUR and a min estimate of 2.74 EUR.
5CV earnings for the last quarter are −0.30 EUR whereas the estimation was −0.24 EUR which accounts for −25.09% surprise. Estimated earnings for the next quarter are −0.23 EUR. See more details about CUREVAC NV earnings.
CUREVAC NV revenue for the last quarter amounts to 7.59 M EUR despite the estimated figure of 20.62 M EUR. In the next quarter revenue is expected to reach 16.97 M EUR.
Yes, you can track CUREVAC NV financials in yearly and quarterly reports right on TradingView.
Like other stocks, 5CV shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade CUREVAC NV stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 16, 2024, the company has 1.05 K employees. See our rating of the largest employees — is CUREVAC NV on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. CUREVAC NV EBITDA is −290.89 M EUR, and current EBITDA margin is −384.87%. See more stats in CUREVAC NV financial statements.